Effect of the timing of recurrence on survival among patients with breast cancer with brain metastasis.

• DOI: 10.1200/jco.2024.42.16_suppl.e14005
• Publication Date: 2024-07-03T19:18:36Z
• Authors: Kendall Miller; Myla S. Strawderman; Sujan Niraula; Ramandeep Babbra; Niraj Neupane; Asis Shrestha; Sugam Gouli; Zeni Kharel; Carey K. Anders; Nimish Mohile; Ruth O'Regan; Carla Isadora Fal...; Anna Weiss; Allison Magnuson; Sarah Stanford; Ajay Dhakal
• Keywords: 03 medical and health sciences; 0302 clinical medicine

e14005 Background: Patients with Metastatic Breast Cancer (MBC) and brain metastasis (BM) have poor prognosis. There is a lack of data on the effects timing MBC diagnosis [de novo (d) vs recurred (r) MBC] BM [dBM later onset (lo) BM] overall survival (OS). We conducted natural history-type study to investigate these among patients. Methods: The for this retrospective single institute was extracted from database patients diagnosed Jan 2010 June 2021. Definitions: dMBC= at initial (Dx); rMBC= prior history early stage BC; dBM= diagnosed< 6 weeks (wk) Dx; loBM= ≥ wk Dx. following endpoints were compared between dMBC rMBC: 1. interval Dx (Interval MBC-BM) 2. OS 3. dBM loBM. Median estimated using Kaplan-Meier method reported 95% confidence intervals (CI). Cohorts Logrank test adjusted other variables Cox models. Results: Interval MBC-BM, Dx, not statistically different rMBC groups in unadjusted analyses (See Table) when multivariate analyses. significantly longer group loBM Table). In model adjusting (age, race, performance status, visceral disease, number >1cm, leptomeningeal BC receptor types), risk death higher (Hazard Ratio, HR = 0.499; p=0.006). group, 28.1% had 45.6% (p=0.083, Chi-square test). Subset analyses: Among median (n=42, OS=44.3 months (m), CI 19.0-Not evaluable (NE)) (n=50, OS=13.7m (6.6-21.4)), p=0.002 (LogRank Test); but there no significant difference (n=9, OS=32.4m (12.9-122.5)) vs. (n=23, OS= 17.8m (6.6-NE)), p=0.885. Conclusions: BC, time diagnosis, did differ those recurrent de MBC. Interestingly, analyses, at/around than whose onset. Earlier-onset disease course could be more sensitive cancer-directed therapies. Studies are needed hypothesis.[Table: see text]